Neurocrine's total assets for Q4 2024 were $3.72B, an increase of 5.20% from the previous quarter. NBIX total liabilities were $1.13B for the fiscal quarter, a 38.34% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.